Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals is a pharmaceutical company that develops and commercializes treatments for rare diseases. The company operates primarily in the endocrinology and metabolic disease segments. Its commercial portfolio comprises eight approved therapies, including Increlex, Alkindi Sprinkle, Khindivi, Galzin, and PKU Golike, as well as generic formulations of carglumic acid, betaine anhydrous, and nitisinone. These medications address conditions such as adrenocortical insufficiency, growth factor deficiency, Wilson disease, and genetic metabolic disorders. The company's end consumers are rare disease patients, often children, and it distributes its therapies through specialty pharmacies to healthcare providers and patients.

The company conducts its commercial sales operations in the United States, and its product Increlex is approved in forty international territories, including the European Union. Eton maintains twelve employees supporting its research and development initiatives. It outsources finished product manufacturing to third-party contract manufacturing organizations situated primarily across the United States and Europe. The provided text does not state the company's headquarters.

Summary of the business section of Eton Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“At December 31, 2025, we had 44 full-time employees, twelve of whom are engaged in research and development activities, twenty-four are engaged in sales and marketing operations and eight of whom are engaged in general corporate and strategy roles.”